Skip to Content

Philip Lorenzi, Ph.D.


Supervisor, Laboratory and Research

Degrees

  • Ph.D. in Pharmaceutics, University of Michigan, Ann Arbor, MI
  • M.S. in Pharmaceutics, University of Michigan, Ann Arbor, MI
  • B.S. in Chemistry, Loyola University Chicago, Chicago, IL


Publications

 

S Claerhout, PL Lorenzi, JN Weinstein, GB Mills. Modulation of autophagy and its potential for cancer therapy.  Drugs Future 2011; 36(12): 919-25.

H Liu, P D’Andrade, S Fulmer-Smentek, PL Lorenzi, KW Kohn, JN Weinstein, Y Pommier, WC Reinhold.  mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.  Mol Cancer Ther 2010; 9(5): 1080-91.

WC Reinhold, MA Reimers, PL Lorenzi, J Ho, UT Shankavaram, MS Ziegler, KJ Bussey, E Kaldjian, S Nishizuka, O Ikediobi, YG Pommier, JN Weinstein. Multifactorial regulation of E-cadherin expression: an integrative study.  Mol Cancer Ther 2010; 9(1): 1-16.

AG Jobson, GT Lountos, PL Lorenzi, J Llamas, J Connelly, JE Tropea, A Onda, S Kondapaka, N Caplen, A Monks, C Self, DS Waugh, RH Shoemaker, Y Pommier. Cellular inhibition of Chk2 kinase and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019.  J Pharmacol Exp Ther 2009; 331(3): 816-26.

PL Lorenzi, WC Reinhold, S Varma, AA Hutchinson, Y Pommier, SJ Chanock, JN Weinstein. DNA fingerprinting of the NCI-60 cell line panel.  Mol Cancer Ther 2009; 8(4): 713-24.

PL Lorenzi, JN Weinstein.  Asparagine synthetase: a new potential biomarker in ovarian cancer. Drug News Perspect 2009; 22(1): 61-4.

PL Lorenzi, MC Ryan, ON Ikediobi, JN Weinstein. ASNS (asparagine synthetase). Atlas Genet Cytogenet Oncol Haematol, http://AtlasGeneticsOncology.org/Genes/ASNSID44323ch7q21.html (

November 2008).

PL Lorenzi, J Llamas, M Gunsior, L Ozbun, WC Reinhold, H Ji, H Kim, PK Goldsmith, MJ Birrer, JN Weinstein. Asparagine synthetase is a biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther 2008; 7(10): 3123-8.

PE Blower, JS Verducci, S Lin, J Zhou, J-H Chung, Z Dai, C-G Liu, W Reinhold, PL Lorenzi, EP Kaldjian, CM Croce, JN Weinstein, W Sadee. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007; 6(5): 1483-91.

SE Martin, TL Jones, CL Thomas, PL Lorenzi, DA Nguyen, T Runfola, M Gunsior, JN Weinstein, PK Goldsmith, E Lader, K Huppi, NJ Caplen. Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res 2007; 35(8): e57.

Z-H Miao, A Player, U Shankavaram, Y-H Wang, DB Zimonjic, PL Lorenzi, Z-Y Liao, H Liu, T Shimura, H-L Zhang, L-H Meng, Y-W Zhang, ES Kawasaki, NC Popescu, MI Aladjem, DJ Goldstein, JN Weinstein, Y Pommier. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res 2007; 67(18): 8752-61.

PL Lorenzi, WC Reinhold, M Rudelius, M Gunsior, U Shankavaram, KJ Bussey, U Scherf, GS Eichler, SE Martin, K Chin, JW Gray, EC Kohn, ID Horak, DD Von Hoff, M Raffeld, PK Goldsmith, NJ Caplen, JN Weinstein. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006; 5(11): 2613-23.

PL Lorenzi, CP Landowski, A Brancale, X Song, LB Townsend, JC Drach, GL Amidon. N-methylpurine DNA glycosylase and 8-oxoguanine DNA glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole. Drug Metab Disp 2006; 34(6): 1070-7.

CP Landowski, PL Lorenzi, X Song, GL Amidon. Nucleoside ester prodrug substrate specificity of carboxylesterase. J Pharmacol Exp Ther 2005; 316(2): 572-80.

PL Lorenzi, CP Landowski, X Song, KZ Borysko, JM Breitenbach, JS Kim, JM Hilfinger, LB Townsend, JC Drach, GL Amidon. Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther 2005; 314(2): 883-90.

X Song, PL Lorenzi, CP Landowski, BS Vig, JM Hilfinger, GL Amidon. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bio-conversion, metabolic bioevasion and hPEPT1-mediated transport. Mol Pharm 2005; 2(2): 157-67.

CP Landowski, X Song, PL Lorenzi, JM Hilfinger, GL Amidon. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res 2005; 22(9): 1510-8.

X Song, BS Vig, PL Lorenzi, JC Drach, LB Townsend, GL Amidon. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl) benzimidazole (BDCRB) as potential substrates of hPEPT1 transporter. J Med Chem 2005; 48(4): 1274-7.

I Kim, X Song, BS Vig, S Mittal, H-C Shin, PJ Lorenzi, GL Amidon. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm 2004; 1(2): 117-27.

BS Vig, PJ Lorenzi, S Mittal, CP Landowski, H Shin, HI Mosberg, JM Hilfinger, GL Amidon. Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res 2003; 20(9):1381-8.

AK El-Qisairi, HA Qaseer, G Katsigras, PJ Lorenzi, U Trivedi, S Tracz, A Hartman, JA Miller, PM Henry. New palladium(II)-catalyzed asymmetric 1,2-dibromo synthesis. Org Lett 2003; 5(4):439-41.

C Shu, H Shen, NS Teuscher, PJ Lorenzi, RF Keep, DE Smith. Role of PEPT2 in peptide/mimetic trafficking at the blood-CSF barrier: studies in rat choroid plexus epithelial cells in primary culture.J Pharmacol Exp Ther 2002; 301(3):820-9.  


© 2014 The University of Texas MD Anderson Cancer Center